- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Small Cell Lung Cancer | Clinical
Roundtable Discussion: Iams Considers Platinum Rechallenge or Other Therapy for Relapsed ES-SCLC
September 22, 2022
During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.
Roundtable Discussion: Kandra Explores Benefit of Chemoimmunotherapy for Small Cell Lung Cancer
August 28, 2022
During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.
Examining Treatment Options for Second-Line ES-SCLC Therapy
August 19, 2022
During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed the data supporting the use of immunotherapy for patients with extensive-stage small cell lung cancer.
Tarlatamab Demonstrates Preliminary Antitumor Efficacy in Heavily Pretreated SCLC
August 11, 2022
Interim findings from the phase 1 DELLphi-300 shows that tarlatamab may induce responses in heavily-pretreated patients with small cell lung cancer.
PARP Inhibitor Regimen Leads to Promising ORR in ES-SCLC
August 08, 2022
The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.
Expert Compares Atezolizumab and Durvalumab as Therapy for ES-SCLC
August 08, 2022
During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.
Irinotecan Liposomal Injection Shows No OS Improvement vs Topotecan in SCLC
August 03, 2022
The phase 3 RESILIENT trial of irinotecan liposomal injection vs topotecan failed to meet its primary end point of overall survival in patients with previously treated small cell lung cancer.
Clinical Commentary: How Immunotherapy Is Used for Treatment of Patients with ES-SCLC and NSCLC
July 27, 2022
At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.
Phase 2 Trial Initiaties DS-7300 Treatment in ES-SCLC
July 26, 2022
Following positive phase 1/2 results of DS-7300 use in patients with extensive-stage small cell lung cancer, a phase 2 study has dosed its first patient with the experimental agent.
Roundtable Discussion: Mohamed Analyzes Data for Understanding ES-SCLC Treatment
July 18, 2022
During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.